You are here

BCRF Grantee Since

2004

Donor Recognition

The Play for P.I.N.K. Award

Area(s) of Focus

Carlos L. Arteaga, MD

Donna S. Hall Chair in Breast Cancer Research
American Cancer Society Clinical Research Professor
Professor of Medicine and Cancer Biology
Director, Breast Cancer Research Program Vanderbilt-Ingram Cancer Center (VICC)
Associate Director for Clinical Research at VICC
Vanderbilt University School of Medicine
Nashville, Tennessee

Current Research

Most estrogen receptor-positive (ER+) breast cancers depend on female hormones and initially respond to anti-estrogen (hormonal) therapies, such as tamoxifen, aromatase inhibitors and fulvestrant. However, many of these cancers eventually become resistant to ER-targeted therapies. Dr. Arteaga’s BCRF research is focused on understanding why ER+ tumors become resistant and developing new approaches to improve clinical outcome. His team has recently discovered two molecules that may be important in the development of resistance and they are currently working to initiate a clinical trial to test drugs that block these proteins in combination with hormonal therapies. These studies and results from the trial will have important clinical implications on improving response to anti-estrogen therapy in patients with ER+ breast cancer.

Bio

Dr. Arteaga trained in Internal Medicine and Medical Oncology at Emory University and the UT Health Sciences Center San Antonio, respectively. He joined Vanderbilt in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. Dr. Arteaga is also Associate Director for Clinical Research, Director of the Breast Cancer Program, and Director of the Center for Cancer Targeted Therapies at the Vanderbilt-Ingram Cancer Center. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes, targeted therapies and biomarkers of drug resistance, and investigator-initiated clinical trials in breast cancer. Since 2002, he has directed the NCI-funded Vanderbilt Breast SPORE. He is a member of the ASCI and the Association of American Physicians. He received the AACR Richard & Hinda Rosenthal Award, a 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from ASCO and the 2011 Brinker Award from the Susan G. Komen Foundation. He has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He is Deputy Editor of Clinical Cancer Research and member of the Editorial Board of Cancer Cell and six other peer-reviewed journals. In 2014, he is serving as the elected President of the AACR.